Gene Therapy Global Market is Projected to Grow at a CAGR of ~19% by 2028

The gene therapy market is witnessing significant momentum as advancements in genetic medicine continue to transform the treatment landscape for several serious and rare diseases. The increasing burden of genetic disorders such as spinal muscular atrophy, hemophilia, and inherited retinal diseases, coupled with growing clinical research activity, is creating substantial opportunities for gene therapy developers. Improvements in gene editing technologies, vector engineering, manufacturing capabilities, and targeted delivery approaches are further supporting market expansion. According to DelveInsight, the global gene therapy market is projected to grow at a CAGR of approximately 19% during the forecast period from 2023 to 2028.

DelveInsight’s Gene Therapy Market Insights report provides a comprehensive assessment of the current and future market landscape, covering market trends, growth drivers, barriers, competitive developments, leading companies, and regional dynamics. The report also examines the evolving pipeline and therapeutic applications that are shaping the future of gene-based medicine.

Explore the latest insights shaping the global gene therapy market - https://www.delveinsight.com/report-store/gene-therapy-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Gene Therapy Market: Key Developments and Industry Landscape

North America is expected to maintain a prominent position in the global gene therapy market during the forecast period. The region benefits from an established healthcare ecosystem, strong research infrastructure, substantial investments in biotechnology, and the presence of several leading pharmaceutical and biotechnology companies. The growing focus on rare diseases and innovative treatment modalities is also contributing to the development of gene therapy programs.

Several prominent companies are actively involved in the gene therapy landscape, including Novartis AG, F. Hoffmann-La Roche Ltd., Ferring B.V., bluebird bio, Inc., Ultragenyx Pharmaceutical Inc., PTC Therapeutics, BioMarin, Biogen, Prevail Therapeutics, and CSL, among others.

The gene therapy sector also experienced several notable developments in January 2024. Vertex Pharmaceuticals announced that CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy, received marketing authorization from the Saudi Food and Drug Authority for sickle cell disease and transfusion-dependent beta thalassemia.

During the same period, Precision BioSciences entered into an agreement with TG Therapeutics involving the development of azercabtagene zapreleucel for potential applications beyond oncology, particularly autoimmune diseases. Kriya Therapeutics also outlined plans to advance its gene therapy programs into clinical development, highlighting the growing pipeline of next-generation genetic medicines.

Bayer AG and Asklepios BioPharmaceutical announced the completion of 18-month data collection from a Phase Ib study evaluating AB-1005 (AAV2-GDNF), an investigational gene therapy being developed for Parkinson’s disease. Meanwhile, MeiraGTx announced a financial transaction involving its remaining interest in an eye-disease treatment collaboration with Johnson & Johnson.

Genascence Corporation also initiated a Phase Ib clinical study of GNSC-001 for knee osteoarthritis. These developments demonstrate the expanding application of gene therapy beyond traditional rare genetic disorders into neurological, ophthalmological, autoimmune, and musculoskeletal conditions.

To read more about the latest highlights related to the gene therapy market, get a snapshot of the key highlights entailed in the Global Gene Therapy Market Report - https://www.delveinsight.com/sample-request/gene-therapy-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Gene Therapy Overview and Therapeutic Potential

Gene therapy is an advanced therapeutic approach designed to treat disease by introducing, removing, replacing, or modifying genetic material within a patient’s cells. Unlike conventional therapies that primarily manage symptoms or disease progression, gene therapy seeks to address underlying genetic mechanisms responsible for disease development.